H, Evron W, Dailey G, Gerich J. Pancreatic beta;-cell dysfunction as the primary genetic lesion in NIDDM. JAMA 1995; 273: 1855-61.
[114] Gerich JE, Pathogenesis and treatment of type 2 (non-insulin-dependent) diabetes mellitus (NIDDM). Horm Metab Res 1996; 28: 404-412.
[115] Davies MJ, Rayman G, Grenfell A, Gray IP, Day JL, Hales CN. Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance. Diabet Med 1994; 11: 434-6.
[116] Mitrakou A, Kelley D, Venemann T, Pangburn J, Reilly J, Gerich H. Role of reduced suppression of hepatic glucose output and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-9.
[117] Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-94.
[118] Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F, Gambordella A, Guigliano D, Onofrio FD, Howard BV, Lowering fatty acids potentiates acute insulin response in first-degree relatives of people with type 2 diabetes. Diabetologia 1998; 41: 1127-32.
[119] Kolb H. Äthiopathogenese und Genetik. In: Berger M, editor. Diabetes mellitus. München: Urban & Schwarzenberg, 1995: 209-14.
[120] Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type 1 diabetes in patients 35-75 years at diagnosis. Diabetes 1986; 35: 237-41.
[121] Hother-Nielsen O, Faber O, Schwartz-Sörensen N, Beck-Nielsen H. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care 1988; 1: 531-7.
[122] Niskanan L, Karjalainen J, Sarlund H, Siitonen O, Uusitopa M. Five-year follow-up of islet cell antibodies in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 402-8.
[123] Canadian-European Diabetes Study Group. Cyclosporin induced remission of IDDM after early intervention: association of 1 year of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988; 37: 1574-82.
[124] Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989; 320: 550-4.
[125] Turner RC, Cull CA, Frighi V, Hohman RR. for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or Insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12.
[126] Brinchmann-Hansen O, Dahl-Jörgensen K, Sandvik L, Hanssen KF. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo Study. BMJ 1992; 304: 19-22.
[127] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
[128] Amthor KF, Dahl-Jörgensen K, Berg TJ, Heier MS, Sandvik L, Aagenaes O, Hanssen KF. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 1994; 37: 579-84.
[129] Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow-up. Diabetologia 1996; 39: 1483-8.
[130] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
[131] Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
[132] Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
[133] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
[134] Abraira C, Colwell J, Nuttwall F, Sawin CT, Hendersen W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS, and the Veterans Affairs Cooperative Study on Glycemic Control and Complications in type 2 Diabetes (VA CSDM) Group. Cardiovascular events and correlates in the Veterans Affairs Feasability Trial. Arch Intern Med 1997; 157: 181-8.
[135] Ito H, Harano Y, Suzuki M, Hattori Y, Tacheuchi M, Inada H, Inoue J, Kawamori R, Murase T, Ouchi Y, Umeda F, Nawata H, Oim H, and the Mtilticlinical Study for Diabetic Macroangiopathy Group. Risk factor analysis for macrovascular complication in non obese NIDDM patients. Multiclinical Study for Diabetic Macroangiopathy (MSDM). Diabetes 1996; 45 (suppl 3): S19-23.
[136] Schleicher E, Nerlich A. The role of hyperglycaemia in the development of diabetic complications. Horm Metab Res 1996; 28: 367-73.
[137] Giardino J, Brownlee M. The biochemical basis of micro-vascular disease. In: Pickup J, William G, editors, Textbook of diabetes. Oxford: Blackwell Science; 1997: 42. 1-16.
[138] Gries FA, Petersen-Braun M, Tschöpe D, Loo J van de. Haemostasis and diabetic angiopathy: pathophysiology and therapeutic concepts. Stuttgart: Georg Thieme Verlag, 1993.
[139] Vlassara H, Bucala R. Advanced glycation and diabetes complications: an update. Diabetes Annu 1995; 9: 227-44.
[140] Tschöpe D, Rösen P. Gerinnungsstörungen bei metabolischem Syndrom und Typ 2 Diabetes. In: Mehnert H, editor. Herz, Gefäszlig;e und Diabetes. Miünchen: Medikon; 1997: 117-32.
[141] Baron AD, Quon MJ. Insulin action and endothelial function. In: Reaven GM, Laws A, editors, Insulin resistance. Totowa, NJ: Humana Press, 1999: 247-63.
[142] Laws A. Insulin resistance and dyslipidemia: implications for coronary heart disease risk. In: Reaven GM, Laws A, editors. Insulin resistance. Totowa, NJ: Humana Press, 1999: 267-80.
[143] Packer L, Rösen P, Tritschler HJ, King GL, Azzi A. Antioxidants in diabetes management. New York: Marcel Dekker; 2000.
[144] Nawroth PP, Borcea V, Bierhaus A, Joswig M, Schiekofer S, Tritschler HJ. Oxidative stress, NF-kB activation, and late diabetic complications. In: Packer L, Rösen P, Tritschler HJ, King GL, Azzi A, editors, Antioxidants in diabetes management. New York: Marcel Dekker; 2000: 185-204.
[145] Idris J, Gray S, Donelley R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2000; 44: 659-73.
[146] Nishigawa T, Edelstein D, Du XL, Yamagishi SI, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
[147] Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing SP 1 glycosylarion. Proc Natl Acad Sci USA 2000; 97: 12222-6.
[148] Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-66.
